Connect Biopharma Holdings
CNTB
20 hedge funds and large institutions have $9.6M invested in Connect Biopharma Holdings in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 7 closing their positions.
3.04% less ownership
Funds ownership: 23.14% → 20.1% (-3%)
20% less funds holding
Funds holding: 25 → 20 (-5)
42% less capital invested
Capital invested by funds: $16.4M → $9.6M (-$6.83M)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
+$36.5K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$17.2K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$14.5K |
| 4 |
JP Morgan Chase
New York
|
+$2.05K |
| 5 |
Renaissance Technologies
New York
|
+$494 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$792K |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$581K |
| 3 |
BlackRock
New York
|
-$248K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$206K |
| 5 |
Citigroup
New York
|
-$62.2K |
CNTB Hedge Fund Activity: Q4 2022 in Review
20 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Connect Biopharma Holdings (CNTB) for Q4 2022, worth a combined $9.6M — down 42% from $16.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CNTB and 2 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 4 added.
The largest buyer was Ergoteles, opening a new position worth an estimated $36.5K. The largest seller was UBS O'Connor, exiting entirely with an estimated $792K sold.
- 20 institutional investors held Connect Biopharma Holdings (CNTB) as of Q4 2022, down from 25 in Q3 2022.
- Funds reported $9.6M of Connect Biopharma Holdings stock for Q4 2022, down 42% quarter-over-quarter.
- 2 funds opened new Connect Biopharma Holdings positions in Q4 2022 and 7 closed out, a net change of -5 holders.
- The largest Connect Biopharma Holdings buyer in Q4 2022 was Ergoteles, an estimated $36.5K added.
- The largest Connect Biopharma Holdings seller in Q4 2022 was UBS O'Connor, an estimated $792K sold.
Based on aggregated 13F filings for Q4 2022.